Singapore markets open in 5 hours 5 minutes

LLY Jan 2024 190.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
177.100.00 (0.00%)
As of 01:55PM EST. Market open.
Full screen
Previous close177.10
Expiry date2024-01-19
Day's range177.10 - 177.10
Contract rangeN/A
Open interest26
  • Yahoo Finance Video

    Weight loss drug hype: It's different this time, analyst says

    Novo Nordisk (NVO), the company behind the popular diabetes and weight-loss drugs Ozempic and Wegovy, is Yahoo Finance's 2023 Company of the Year. It's not, however, the only drugmaker to be making a splash in the weight-loss drug space. Eli Lilly (LLY) has its own medicines, Mounjaro and Zepbound, the latter which just recently became available at US pharmacies. Even though drugmakers have been working on weight-loss drugs for years, "it really does feel like this time it's different for obesity drugs," Morningstar Director of Equity Strategy Damien Conover tells Yahoo Finance. Conover says Novo and Lilly will "dominate" the obesity drug market over the next couple of years, though there will eventually be more competition that will force prices lower. ThirdBridge Global Sector Lead for Healthcare Lee Brown argues that eventually "it's going to be harder and harder for payers to push back" against paying for these drugs given the longer-term benefits they can provide. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

  • Reuters

    UPDATE 2-Weight loss from Lilly's Zepbound reversed after stopping treatment, study shows

    Patients on Eli Lilly's weight-loss drug Zepbound substantially regained weight nearly a year after stopping treatment, according to full results of a study published on Monday. Meanwhile, those who continued the treatment experienced an additional 5.5% weight reduction during the 52-week period, data from the study showed. Shares of Eli Lilly fell over 4% in morning trading.

  • PR Newswire

    Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks

    Detailed results from SURMOUNT-4, which showed Zepbound™ (tirzepatide) injection achieved superior mean percent change in body weight compared to placebo in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes, were published in The Journal of the American Medical Association (JAMA). Zepbound met the primary endpoint of mean percent change in body weight, and all key secondary endpoints for both estimandsi,ii, compared to placebo 52 weeks after randomiza